brain
           sciences
Erratum
Erratum: Pagonabarraga, J.; et al. A Spanish
Consensus on the Use of Safinamide for Parkinson’s
Disease in Clinical Practice. Brain Sci. 2020, 10, 176
Javier Pagonabarraga 1,2,3, *, José Matías Arbelo 4,5 , Francisco Grandas 6,7 ,
Maria-Rosario Luquin 8,9 , Pablo Martínez Martín 10,11 , Maria Cruz Rodriguez-Oroz 12,13 ,
Francesc Valldeoriola 14,15 and Jaime Kulisevsky 1,2,3,16,17
 1    Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona,
      Spain; jkulisevsky@santpau.cat
 2    Department of Medicine, Autonomous University of Barcelona, 08193 Barcelona, Spain
 3    Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
 4    Movement Disorders Unit, Neurology Department, Hospital Universitario San Roque, 35001 Las Palmas,
      Spain; jmarbelo@gmail.com
 5    Department of Medicine, Universidad Fernando Pessoa-Canarias, 35450 Las Palmas, Spain
 6    Movement Disorders Unit-CSUR, Neurology Department, Hospital General Universitario Gregorio
      Marañón, 28007 Madrid, Spain; francisco.grandas@salud.madrid.org
 7    Department of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain
 8    Movement Disorders Unit, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain; rluquin@unav.es
 9    Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain
 10   Instituto de Salud Carlos III, 28029 Madrid, Spain; pmm650@hotmail.com
 11   Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED),
      28031 Madrid, Spain
 12   Neurology and Neuroscience Unit, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain;
      mcroroz@unav.es
 13   Centre for Applied Medical Research (CIMA), 31008 Pamplona, Spain
 14   Neurosciences Institut, Hospital Clinic de Barcelona, 08036 Barcelona, Spain; FVALLDE@clinic.ub.es
 15   Department of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain
 16   Biomedical Research Institute (IIB-Sant Pau), 08041 Barcelona, Spain
 17   Department of Medicine, Universitat Oberta de Catalunya, 08018 Barcelona, Spain
 *    Correspondence: JPagonabarraga@santpau.cat; Tel.: +34-647-618-844; Fax: +34-935-565-748
                                                                                                    



 Received: 11 May 2020; Accepted: 15 May 2020; Published: 22 May 2020                               





     We would like to submit the following erratum to our recently published paper [1] due to the errors
in the abstract. We request (1) the removal of the word “motor” from the first line of the abstract, so that
the sentence reads: “Safinamide is an approved drug for the treatment of fluctuations in Parkinson’s
disease (PD)”, and (2) that the word “OFF” is changed to “ON” in line 6 of the abstract, so that the
sentence reads: “Safinamide significantly improves the mean daily ON time without troublesome
dyskinesias.”
     We apologize for any inconvenience caused to our readers.

Conflicts of Interest: The authors declare no conflict of interest.




Brain Sci. 2020, 10, 313; doi:10.3390/brainsci10050313                          www.mdpi.com/journal/brainsci
Brain Sci. 2020, 10, 313                                                                                      2 of 2



Reference
1.    Pagonabarraga, J.; Arbelo, J.M.; Grandas, F.; Luquin, M.-R.; Martínez Martín, P.; Rodríguez-Oroz, M.C.;
      Valldeoriola, F.; Kulisevsky, J. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in
      Clinical Practice. Brain Sci. 2020, 10, 176. [CrossRef] [PubMed]

                           © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
                           article distributed under the terms and conditions of the Creative Commons Attribution
                           (CC BY) license (http://creativecommons.org/licenses/by/4.0/).